| Trial ID: | L0082 |
| Source ID: | NCT02696941
|
| Associated Drug: |
Metformin
|
| Title: |
SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis
|
| Acronym: |
SMASH
|
| Status: |
Completed
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Non-alcoholic Fatty Liver Disease
|
| Interventions: |
Drug: Metformin|Drug: SGLT2 inhibitor
|
| Outcome Measures: |
Hepatic steatosis|% contribution of newly synthesised lipid to circulating triglyceride levels|Global insulin sensitivity|Hepatic insulin sensitivity|Intrabdominal fat
|
| Sponsor/Collaborators: |
University of Oxford
|
| Gender: |
All
|
| Age: |
18 Years to 70 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
20
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
|
| Start Date: |
February 2016
|
| Completion Date: |
April 1, 2018
|
| Results First Posted: |
--
|
| Last Update Posted: |
May 4, 2018
|
| Locations: |
University of Oxford, Oxford, United Kingdom
|
| URL: |
https://ClinicalTrials.gov/show/NCT02696941
|
